Market revenue in 2023 | USD 430.0 million |
Market revenue in 2030 | USD 719.4 million |
Growth rate | 7.6% (CAGR from 2023 to 2030) |
Largest segment | Molecular diagnostics |
Fastest growing segment | Immunoassays |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Immunoassays, Hematology and Coagulation, Molecular Diagnostics, Microbiology, Clinical Chemistry, Histology/Cytology, Flow Cytometry, Mass Spectroscopy |
Key market players worldwide | Quest Diagnostics Inc, 23andMe Holding Co Class A, Abbott Laboratories, Guardant Health Inc, NeoGenomics, Siemens Healthineers AG ADR, Qiagen NV, Illumina Inc, Roche Holding AG ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to laboratory developed tests market will help companies and investors design strategic landscapes.
Molecular diagnostics was the largest segment with a revenue share of 26.53% in 2023. Horizon Databook has segmented the UK laboratory developed tests market based on immunoassays, hematology and coagulation, molecular diagnostics, microbiology, clinical chemistry, histology/cytology, flow cytometry, mass spectroscopy covering the revenue growth of each sub-segment from 2018 to 2030.
The LDT market in the UK is highly competitive, with several companies offering a wide range of diagnostic solutions. The UK has several key companies in the diagnostic industry, including Roche, Illumina, and Thermo Fisher Scientific, as well as smaller companies that focus on niche areas of diagnostics.
The LDT market in the UK observed significant growth owing to advanced technology and increasing demand for innovative diagnostic solutions. There has been a particular focus on developing new LDTs for early detection and diagnosis of cancer, as well as for the diagnosis of infectious diseases like SARS-CoV-2.
In addition, the availability of the Cobas Omni Utility Channel offers professionals to conduct CE-IVD assays and design their LDTs. In August 2020, Thermo Fisher announced receiving CE mark certification for its OmniPATH Combi SARS CoV 2 IgG ELISA Test. The company developed this test in collaboration with Oxford University to expand the company’s serology portfolio for enhanced COVID-19 epidemiological studies.
Horizon Databook provides a detailed overview of country-level data and insights on the UK laboratory developed tests market , including forecasts for subscribers. This country databook contains high-level insights into UK laboratory developed tests market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account